Stock Notes

Cohance Lifesciences

Every Finvezto stock note on Cohance Lifesciences, dated and newest first. Coverage spans pharma, pharmaceuticals.

2 notes and counting
21 Sep 2026
Cohance Lifesciences drew a Form 483 with five observations after the USFDA inspected its Jaggaiahpet API plant from 14 to 19 September.
The same site cleared a USFDA audit with zero observations in September 2025. The company has not said what the observations cover, so the commercial read is unavailable for now.
05 Sep 2026
Cohance Lifesciences received a Form 483 with four observations after a US FDA inspection of its Shamshabad formulations plant ended on 4 September.
The observations have not been disclosed and corrective action is under way. A 483 is not a final finding, but the response decides whether the site stays clear for US supply.
Finvezto Membership

Get the research behind the notes

Stock notes are the free daily layer. The membership carries the full Flexi-Wealth system: an ETF core portfolio with monthly rebalancing signals, fifteen quality-momentum stocks with exact weightages every month, options income and hedging recommendations, and the institutional data toolkit. One flat membership covers everything.

Become a Member Read free sample research →

Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630. Stock notes are market commentary for general information and education. They are not investment advice, not a recommendation to buy or sell, and do not account for any individual's financial situation. Investment in securities is subject to market risks. Please read all related documents carefully before investing. Past performance is not a guarantee of future results.